Adial pharmaceuticals, inc. (ADIL)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Operating Expenses:
Research and development expenses

4,333

3,965

2,809

2,133

999

368

0

0

0

0

0

General and administrative expenses

3,962

4,279

4,434

7,181

7,897

6,618

0

0

0

0

0

Equity-based compensation

-

-

-

-

-

-

-

-

-

0

0

Total Operating Expenses

8,295

8,244

7,244

9,314

8,896

6,987

0

0

0

0

0

Loss From Operations

-8,295

-8,244

-7,244

-9,314

-8,896

-6,987

0

0

0

0

0

Other Income (Expense)
Interest income

110

95

0

0

0

-

-

-

-

0

0

Loss on debt extinguishments

-

-

-

-

-

-3,484

0

0

0

0

0

Warrant modification expense

-

-441

0

0

0

-

-

-

-

-

-

Interest and financing charges

-

-

-

-

-

1,167

0

0

0

0

-

Interest expense

-

-

-

-

-

-

-

-

-

-

0

Total other income (expense)

110

-346

-557

-4,962

-5,038

-4,644

0

0

0

0

0

Loss Before Provision For Income Taxes

-8,185

-8,591

-7,802

-14,277

-13,935

-11,631

0

0

0

0

0

Benefit from income taxes

-

-

-

-

-

-

-

-

-

0

0

Net Loss

-8,185

-8,591

-7,802

-14,277

-13,935

-11,631

0

0

0

0

0

Net loss per share, basic and diluted

-0.22

-0.16

-0.17

-0.21

-0.33

-0.34

-1.48

-0.50

-0.12

-0.09

-0.08

Weighted average shares, basic and diluted

10,497

10,683

10,252

10,223

8,250

6,665

5,546

3,557

3,268

3,267

3,267